Biography
Maarten IJzerman is Dean of Erasmus School of Health Policy & Management and Professor of Cancer Health Services Research in Erasmus University. He also is (fractional) Professor in the Melbourne School of Population and Global Health and University of Melbourne Centre for Cancer Research.
Maarten studied biomedical sciences (Radboud University Nijmegen) and received his PhD in biomedical engineering (University of Twente).
In his research he takes a systems approach to health (technology) innovation and cancer management. He leads work in genomics enable precision oncology including improving cancer outcomes across the whole episode of care. Current initiatives aim to promote access to cancer care across the globe, with an emphasis on global health challenges and healthcare sustainability.
Maarten is an INSEAD alumnus (International Directors Program, Singapore) and received certificates from University of York (Health Economics) and Colombia University (Corporate Finance) and serves as a non-executive board member in the non-profit sector.
Erasmus School of Health Policy & Management
Dean | Erasmus School of Health Policy & Management
- ijzerman@eshpm.eur.nl
- Room
- J7-19
- Location
- Burg. Oudlaan 50, Rotterdam
Erasmus School of Health Policy & Management
Full professor | Health Services Management & Organisation (HSMO)
- ijzerman@eshpm.eur.nl
- Room
- J7-19
- Location
- Burg. Oudlaan 50, Rotterdam
More information
Work
- William V Padula, Noemi Kreif, David J Vanness, Blythe Adamson, Juan-David Rueda, Federico Felizzi, Pall Jonsson, Maarten J IJzerman, Atul Butte & William Crown (2022) - Machine Learning Methods in Health Economics and Outcomes Research-The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force - Value in Health, 25 (7), 1063-1080 - doi: 10.1016/j.jval.2022.03.022 - [link]
- Praveen Thokala, Nancy Devlin, Kevin Marsh, Rob Baltussen, Meindert Boysen, Zoltan Kalo, Thomas Longrenn, Filip Mussen, Stuart Peacock, John Watkins & Maarten Ijzerman (2016) - Multiple criteria decision analysis for health care decision making - An introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force - Value in Health, 19 (1), 125-137 - doi: 10.1016/j.jval.2015.12.003 - [link]
- Sophie O’Haire, Koen Degeling, Fanny Franchini, Ben Tran, Stephen J. Luen, Clara Gaff, Kortnye Smith, Stephen Fox, Jayesh Desai & Maarten IJzerman (2022) - Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm - Targeted Oncology, 17 (5), 539-548 - doi: 10.1007/s11523-022-00910-0 - [link]
- A. Brett Hauber, Juan Marcos González, Catharina G.M. Groothuis-Oudshoorn, Thomas Prior, Deborah A. Marshall, Charles Cunningham, Maarten J. IJzerman & John F.P. Bridges (2016) - Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force - Value in Health, 19 (4), 300-315 - doi: 10.1016/j.jval.2016.04.004 - [link]
- Maarten J. Ijzerman & Lotte M.G. Steuten (2011) - Early assessment of medical technologies to inform product development and market access: A review of methods and applications - Applied Health Economics and Health Policy, 9 (5), 331-347 - doi: 10.2165/11593380-000000000-00000 - [link]
- Martin Vu, Koen Degeling, Ella R. Thompson, Piers Blombery, David Westerman & Maarten J. IJzerman (2022) - Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review - European Journal of Haematology, 108 (6), 469-485 - doi: 10.1111/ejh.13755 - [link]
- Mussab Fagery, Hadi A Khorshidi, Stephen Q Wong, Martin Vu & Maarten IJzerman (2023) - Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review - PharmacoEconomics, 41 (10), 1229-1248 - doi: 10.1007/s40273-023-01292-5 - [link]
- Koen Degeling, Maarten J. IJzerman, Catharina G.M. Groothuis-Oudshoorn, Mira D. Franken, Miriam Koopman, Mark S. Clements & Hendrik Koffijberg (2022) - Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer - Value in Health, 25 (1), 104-115 - doi: 10.1016/j.jval.2021.07.016 - [link]
- Joost J. Enzing, Saskia Knies, Jop Engel, Maarten J. IJzerman, Beate Sander, Rick Vreman, Bert Boer & Werner B.F. Brouwer (2022) - Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price?: A study of reimbursement reports - Cost Effectiveness and Resource Allocation, 20 (1) - doi: 10.1186/s12962-022-00383-y - [link]
- Sarah Glewis, Marliese Alexander, Senthil Lingaratnam, Benjamin Lee, Ian Campbell, Mei Krishnasamy, Maarten IJzerman, Mussab Fagery, Sam Harris, Chloe Georgiou, Craig Underhill, Mark Warren, Robert Campbell, Jennifer Martin, Jeanne Tie & Michael Michael (2022) - Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial - Acta Oncologica, 61 (9), 1136-1139 - doi: 10.1080/0284186x.2022.2109423 - [link]
Laboratorium Microbiologie
- Start date approval
- januari 2023
- End date approval
- november 2025
- Place
- HENGELO
- Description
- Lid Raad van Toezicht
Erasmus Centrum voor Zorgbestuur b.v.
- Start date approval
- juli 2023
- End date approval
- juni 2026
- Place
- ROTTERDAM
- Description
- Lid Raad van Commissarisen ECZB b.v. namens de EUR
Erasmus Trust Fund
- Start date approval
- september 2023
- End date approval
- augustus 2026
- Place
- ROTTERDAM
- Description
- Lid Bestuur Erasmus Trust Fund
University of Melbourne
- Start date approval
- november 2023
- End date approval
- november 2026
- Place
- MELBOURNE
- Description
- Visiting professor honorary
Universiteit Twente
- Start date approval
- december 2023
- End date approval
- december 2024
- Place
- ENSCHEDE
- Description
- Gastregistratie
International Society for Pharmacoeconomics ISPOR
- Start date approval
- februari 2024
- End date approval
- februari 2027
- Place
- PHILADELPHIA
- Description
- Chair Health Sciences Policy Council
Medical innovation
- Level
- master
- Year Level
- master
- Year
- 2023
- Course Code
- BM02MBI
Thesis HCM
- Level
- master
- Year Level
- master
- Year
- 2023
- Course Code
- GW4030MV
